Mankind Pharma eyes ₹9,000 cr via debt to stitch BSV deal

The average blended cost of the debt is likely to be around 8.50% with the firm seeking to borrow money over one- to-five years, said three people familiar with the plans. "Bankers have already approached large mutual funds to place the debt, which will range from one year and may go up to five years looking at the demand," said one of the persons.